Diadexus, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company's total revenues were $4.5 million, compared to $4.6 million for the second quarter of 2015 and $7.3 million for the third quarter of 2014. The year-over-year decreases are primarily attributable to a decrease in service revenues related to a GSK agreement which completed during the fourth quarter of 2014 and lower PLAC ELISA product sales. The company's net loss for the quarter was $1.3 million, or $0.34 per basic and diluted share, compared to a net loss of $1.6 million, or $0.44 per basic and diluted share, in the third quarter of 2014. Loss from operations was $0.86 million compared with $0.94 million a year ago. Loss before income tax was $1.3 million compared with $1.6 million a year ago.

For the nine months, the company's total revenues were $14.6 million, compared to $20.5 million for the nine months ended September 30, 2014. This decrease is primarily attributable to $3.6 million in service revenues related to a GSK agreement which completed during the fourth quarter of 2014 and lower PLAC ELISA product sales. The company's net loss for the period was $5.7 million, or $1.47 per basic and diluted share, compared to a net loss of $6.2 million, or $1.68 per basic and diluted share, for the nine months ended September 30, 2014. Loss from operations was $4.3 million compared with $5.1 million a year ago. Loss before income tax was $5.6 million compared with $6.1 million a year ago.